Scarica l'app Stockscreener
3.62
2.43%
-0.09
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Galectin Therapeutics Inc Borsa (GALT) Ultime notizie
Galectin Therapeutics (NASDAQ:GALT) Stock Price Breaks Above 200 Day Moving AverageHere's Why - MarketBeat
Galectin Therapeutics Reports Fiscal Year 2025 10-K Highlighting Belapectin Clinical Progress - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Galectin Therapeutics stock gets a Phase 3 protocol update - AD HOC NEWS
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 - The Manila Times
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 - Yahoo Finance
Galectin: $105M Debt Conversion Clears The Balance Sheet, But Phase 3 Partnership Is Critical - Seeking Alpha
Galectin Therapeutics seeks 250 million shares: what it means for Galectin Therapeutics stock - ad-hoc-news.de
Galectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Galectin Therapeutics stock falls 2.22 percent as trial advances - AD HOC NEWS
Galectin Therapeutics stock holds a $399.36 million valuation - AD HOC NEWS
Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Galectin Therapeutics stock holds steady as investors await next clinical updates - AD HOC NEWS
Galectin Therapeutics stock holds recent gains after phase 2b trial update - AD HOC NEWS
Galectin Therapeutics Inc. (GALT) Key Financial Ratios – Valuation, Profitability & More - Value Research
Galectin Therapeutics at H.C. Wainwright: belapectin nears phase III - Investing.com
Why Is Galectin Therapeutics (NASDAQ:GALT) Breaking Out Now? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Stock Crosses Above 200-Day Moving AverageHere's Why - MarketBeat
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
A drug company will present in New York Sept. 14. Galectin will meet investors there. - Stock Titan
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Galectin Therapeutics Stock Price Forecast. Should You Buy GALT? - StockInvest.us
Galectin Therapeutics (NASDAQ:GALT): Can Momentum Outrun Weak Results? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Galectin Therapeutics Inc. (GALT) Peer Comparison – Compare with Others - Value Research
Galectin Therapeutics Inc. (GALT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Galectin Therapeutics (NASDAQ:GALT): Is Momentum Turning Stronger? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Galectin Therapeuti - The National Law Review
Galectin (GALT) Q1 2026 Earnings: The EPS Result Is Below Expectation for the Current Session; Share Move - vinanet.vn
Galectin (GALT) Today: Posts a 5.43% Gain to $3.88 in the Current Update; Technical Setup: the Price Remains Bounded by the Supplied Support and Resistance on the DayTriple MA Cross - vinanet.vn
Liver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight - PR Newswire UK
Galectin (GALT) EPS and Revenue: EPS Misses Its Estimate; Trading Move: The Stock Loses 0.63% in the Available RecordUpward Estimate Revision - vinanet.vn
Galectin (GALT) Earnings Update: Profit Per Share Falls Below Its Benchmark in the Reported Period; Market Response - vinanet.vn
HC Wainwright Analysts Lift Earnings Estimates for GALT - MarketBeat
Galectin Therapeutics (GALT) Holds Gains at $3.49 After 1.45% Advance — Key Levels in FocusSuperTrend Flip - vinanet.vn
Galectin Therapeutics (GALT) Holds Gains at $3.49 After 1.45% Advance — Key Levels in FocusChart Pattern Alerts - dars.gov.et
H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results - MarketBeat
Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen - scanx.trade
Galectin Therapeutics Q2 Net Loss Widens to $9.1M as Derivative Charges Rise - Minichart
Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com - Investing.com Canada
Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100 - GuruFocus
Galectin Therapeutics Reports June 30, 2026 Financial Results - TradingView
Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol - TradingView
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update - marketscreener.com
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):